195 related articles for article (PubMed ID: 11237731)
1. A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
Ariyoshi N; Sawamura Y; Kamataki T
Biochem Biophys Res Commun; 2001 Mar; 281(3):810-4. PubMed ID: 11237731
[TBL] [Abstract][Full Text] [Related]
2. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
3. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
Inoue K; Yamazaki H; Shimada T
Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384
[TBL] [Abstract][Full Text] [Related]
4. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
5. Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies.
Soucek P
Arch Biochem Biophys; 1999 Oct; 370(2):190-200. PubMed ID: 10510277
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Oscarson M
Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
[TBL] [Abstract][Full Text] [Related]
7. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
Nunoya K; Yokoi T; Kimura K; Inoue K; Kodama T; Funayama M; Nagashima K; Funae Y; Green C; Kinoshita M; Kamataki T
Pharmacogenetics; 1998 Jun; 8(3):239-49. PubMed ID: 9682269
[TBL] [Abstract][Full Text] [Related]
8. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
9. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
12. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
13. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
Oscarson M; Gullstén H; Rautio A; Bernal ML; Sinues B; Dahl ML; Stengård JH; Pelkonen O; Raunio H; Ingelman-Sundberg M
FEBS Lett; 1998 Nov; 438(3):201-5. PubMed ID: 9827545
[TBL] [Abstract][Full Text] [Related]
14. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.
Ujjin P; Satarug S; Vanavanitkun Y; Daigo S; Ariyoshi N; Yamazaki H; Reilly PE; Moore MR; Kamataki T
Pharmacogenetics; 2002 Apr; 12(3):241-9. PubMed ID: 11927840
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
16. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin.
Hadidi H; Zahlsen K; Idle JR; Cholerton S
Food Chem Toxicol; 1997 Sep; 35(9):903-7. PubMed ID: 9409631
[TBL] [Abstract][Full Text] [Related]
17. Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T
FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612
[TBL] [Abstract][Full Text] [Related]
18. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
19. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP.
Kitagawa K; Kunugita N; Katoh T; Yang M; Kawamoto T
Biochem Biophys Res Commun; 1999 Aug; 262(1):146-51. PubMed ID: 10448083
[TBL] [Abstract][Full Text] [Related]
20. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T
Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
